Jump to main content
Jump to site search

Issue 3, 2021
Previous Article Next Article

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses

Author affiliations

Abstract

WHO has declared COVID-19 a pandemic, which has affected the whole world and has caused unprecedented social and economic disruption. Since the emergence of the disease, several druggable targets have been suggested including 3-chymotrypsin-like protease (3CLpro), spike, RNA-dependent RNA polymerase (RdRp), and the papain-like protease (PLpro) computational approach. From the beginning, viral replication has been the main focus for any antiviral drug development for viral diseases, including HCV, influenza virus, zika virus, norovirus, measles, dengue virus, and coronaviruses. This review lists the nucleoside, nucleotide, and non-nucleoside RdRp inhibitor analogues of various viral diseases that may be evaluated for drug development to treat COVID-19.

Graphical abstract: Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses

Back to tab navigation

Article information


Submitted
17 Sep 2020
Accepted
26 Nov 2020
First published
23 Dec 2020

RSC Med. Chem., 2021,12, 306-320
Article type
Review Article

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses

R. Kumar, S. Mishra, Shreya and S. K. Maurya, RSC Med. Chem., 2021, 12, 306
DOI: 10.1039/D0MD00318B

Social activity

Search articles by author

Spotlight

Advertisements